key: cord-0851535-500iwm2g
authors: Laterza, Riccardo; Schirinzi, Annalisa; Bruno, Rossella; Genco, Rosa; Contino, Renato; Ostuni, Angelo; Di Serio, Francesca
title: SARS‐CoV‐2 antibodies: Comparison of three high‐throughput immunoassays versus the neutralization test
date: 2021-05-05
journal: Eur J Clin Invest
DOI: 10.1111/eci.13573
sha: 3d834f4cd50d53834cf075ddf728883470571a56
doc_id: 851535
cord_uid: 500iwm2g

On March 11, 2020 the World Health Organization (WHO) declared the novel coronavirus (SARS-CoV-2) outbreak a global pandemic.1 Currently, no specific therapy has proved to be effective against the infection. With the approval by WHO2 of the first vaccine for emergency use against SARS-CoV-2 on December 31, 2020, it is important to understand the strength and duration of immunity after administration, which is induced by neutralizing anti-SARS-CoV-2 S antibodies (nAbs).3 The same antibodies are also present in individuals once the SARS-CoV-2 infection is resolved, at levels that depend on the duration and severity of clinical symptoms.4 The efficacy of passive antibody therapy has been associated with the concentration of nAbs in the convalescent plasma (CP) of recovered patients.5,6 Thus, it would be useful to immediately identify donors with high nAbs titers. The gold-standard test used to detect nAbs is the plaque reduction neutralization test (PRNT).

On 11 March 2020, the World Health Organization (WHO) declared the novel coronavirus (SARS-CoV-2) outbreak a global pandemic. 1 Currently, no specific therapy has proved to be effective against the infection. With the approval by WHO 2 of the first vaccine for emergency use against SARS-CoV-2 on 31 December 2020, it is important to understand the strength and duration of immunity after administration, which is induced by neutralizing anti-SARS-CoV-2 antibodies (nAbs). 3 The same antibodies are also present in individuals once the SARS-CoV-2 infection is resolved, at levels that depend on the duration and severity of clinical symptoms. 4 The efficacy of passive antibody therapy has been associated with the concentration of nAbs in the convalescent plasma (CP) of recovered patients. 5, 6 Thus, it would be useful to immediately identify donors with high nAbs titres. The gold-standard test used to detect nAbs is the plaque reduction neutralization test (PRNT). 7 However, neutralization assays are timeand cost-consuming, as well as being limited in availability, since they require biosafety level 3 laboratories with qualified staff. 8 Several manufacturers have developed immunoassays compatible with global laboratory infrastructures for the COVID-19 emergency, enabling widespread testing of hundreds to thousands of samples per day. Recently, commercial SARS-CoV-2 antibody immunoassays have focused on the receptor-binding domain (RBD) of the spike protein (S), 9 ,10 which appears to be the main antigen responsible for eliciting neutralizing antibodies. 5, 9, 11, 12 We aimed to investigate the correlation between nAbs titres identified by PRNT and the Maglumi 2019-nCoV IgG assay (Snibe, Shenzhen, China) with spike protein-and nucleocapsid (N)-based target, the Elecsys Anti-SARS-CoV-2 S assay (Roche, Basel, Switzerland) and the Maglumi SARS-CoV-2 S-RBD IgG assay, both of which target the spike protein RBD. Residual serum samples from 118 potential candidates for COVID-19 CP donation, with a confirmed negative PCR for COVID-19, were collected. The samples had been tested previously by PRNT, with the following distribution of titres: 1:20 in 3.4% of samples, 1:40 in 29.7%, 1:80 in 20.3%, 1:160 in 17.8% and 1:320 in 28.8%. The immunoassay signal values ranged from 0.45 to 2294.00 U/mL (median = 146.00 U/mL, IQR = 48.00-389.00 U/mL), from 2.10 to 791.70 AU/mL (median = 35.92 AU/mL, IQR = 21.82-92.52 AU/mL) and from 0.01 to 40.13 AU/mL (median = 4.07 AU/mL, IQR = 1.33-6.82 AU/ mL) for the Elecsys Anti-SARS-CoV-2 S, Maglumi SARS-CoV-2 S-RBD IgG and Maglumi 2019-nCoV IgG assays, respectively. The overall difference in median serological test values among the titre groups was statistically significant. The reported data are shown in Figure 1 . Using the predefined assay thresholds to establish whether the test results are positive or negative (0.8 U/mL for Elecsys Anti-SARS-CoV-2 S, 1 AU/mL for both Maglumi SARS-CoV-2 S-RBD IgG and Maglumi 2019-nCoV IgG assays), 21.37% of samples were below the threshold for the S/N IgG assay but were reactive for the RBD Ig assays. The simple linear regression analysis performed on the transformed data showed that there is a stronger positive association between serological test values and the PRNT for the Roche assay (R 2 = 0.566, P < .0001) than for the Maglumi RBD IgG (R 2 = 0.372, P <.0001) and the Maglumi S/N IgG assays (R 2 = 0.149, P < .0001). Moreover, the Spearman test confirmed a strong positive linear relationship between RBD Ig antibodies and neutralization titres: rs = 0.767; P < .0001 for the Roche total RBD Ig assay; and rs = 0.643; P < .0001 for the Maglumi RBD IgG assay, whereas the magnitude of the correlation between the assay targeting S-binding IgG antibodies (Maglumi S/N IgG) and neutralization activity is weaker: rs = 0.395, P < .0001 ( Figure 2 ). Owing to the difficulty finding CP donors with a neutralizing titre of at least 1:160 for human passive immunization studies, a titre of 1:80 was considered to be acceptable if an alternative matched unit is not available. For this reason, we evaluated the performance of the immunoassays to detect nAbs titres ≥1:80 through receiver operating characteristic (ROC) curves (Figure 3 ): the area under the curve (AUC) for the Roche assay (AUC = 0.973) was greater than for the other two assays (AUC = 0.917 for Maglumi RBD IgG and AUC = 0.796 for Maglumi S/N IgG). We selected optimal cut-offs as predictors, using the maximum value of the Youden index, which maximizes the sum of sensitivity and specificity, as shown in Table 1 . Compared with other studies, which show that anti-S IgG antibody titres correlate with the plaque reduction neutralization test, [13] [14] [15] we observed that the Roche total RBD Ig assay showed the best correlation . 

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

who-issue s-its-first -emerg ency-use-valid ation -for-a-covid -19-vacci ne-and-empha sizes -need-for-equit able-globa l-access

Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma

The receptorbinding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Characterization of a pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: a population-based study

Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program

SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test